Search

Your search keyword '"Lai, Chih-Yun"' showing total 27 results
Start Over Author "Lai, Chih-Yun"
27 results on '"Lai, Chih-Yun"'

1. Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80–Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates

Author

Preston, Kendall B., Wong, Teri Ann S., Lieberman, Michael M., To, Albert, Lai, Chih-Yun, Granados, Alex, Thomasson, Holly, Misamore, John, Yalley-Ogunro, Jake, Cabus, Mehtap, Andersen, Hanne, Donini, Oreola, Lehrer, Axel T., and Randolph, Theodore W.

Published
2022
Full Text
View/download PDF

4. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinski, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, Mongkolsapaya, Juthathip, and Screaton, Gavin R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Prevention, Infectious Diseases, Immunization, Biotechnology, Rare Diseases, Vector-Borne Diseases, Biodefense, Emerging Infectious Diseases, Infection, Good Health and Well Being, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Biological Assay, Cell Line, Dengue, Dengue Virus, Enzyme-Linked Immunosorbent Assay, Humans, Immunoblotting, Viral Envelope Proteins, Biochemistry and cell biology
Abstract

Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.

Published
2015

6. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant

Author

To, Albert, primary, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Thompson, Karen, additional, Ball, Aquena H., additional, Pessaint, Laurent, additional, Greenhouse, Jack, additional, Daham, Nisrine, additional, Cook, Anthony, additional, Narvaez, Brandon, additional, Flinchbaugh, Zack, additional, Van Ry, Alex, additional, Yalley-Ogunro, Jake, additional, Andersen Elyard, Hanne, additional, Lai, Chih-Yun, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2022
Full Text
View/download PDF

7. Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

Author

To, Albert, primary, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Thompson, Karen, additional, Pessaint, Laurent, additional, Greenhouse, Jack, additional, Daham, Nisrine, additional, Cook, Anthony, additional, Narvaez, Brandon, additional, Flinchbaugh, Zack, additional, Ry, Alex Van, additional, Yalley-Ogunro, Jake, additional, Elyard, Hanne Andersen, additional, Lai, Chih-Yun, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2021
Full Text
View/download PDF

8. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Author

Lai, Chih-Yun, primary, To, Albert, additional, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Clements, David E., additional, Senda, James T., additional, Ball, Aquena H., additional, Pessaint, Laurent, additional, Andersen, Hanne, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2021
Full Text
View/download PDF

12. Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice

Author

To, Albert, primary, Medina, Liana O., additional, Mfuh, Kenji O., additional, Lieberman, Michael M., additional, Wong, Teri Ann S., additional, Namekar, Madhuri, additional, Nakano, Eileen, additional, Lai, Chih-Yun, additional, Kumar, Mukesh, additional, Nerurkar, Vivek R., additional, and Lehrer, Axel T., additional

Published
2018
Full Text
View/download PDF

14. Erratum: Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinsky, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2015
Full Text
View/download PDF

15. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinski, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2014
Full Text
View/download PDF

17. High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection

Author

Tsai, Wen-Yang, primary, Lai, Chih-Yun, additional, Wu, Yi-Chieh, additional, Lin, Hong-En, additional, Edwards, Carolyn, additional, Jumnainsong, Amonrat, additional, Kliks, Srisakul, additional, Halstead, Scott, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin R., additional, and Wang, Wei-Kung, additional

Published
2013
Full Text
View/download PDF

20. Analysis of Epitopes on Dengue Virus Envelope Protein Recognized by Monoclonal Antibodies and Polyclonal Human Sera by a High Throughput Assay

Author

Lin, Hong-En, primary, Tsai, Wen-Yang, additional, Liu, I-Ju, additional, Li, Pi-Chun, additional, Liao, Mei-Ying, additional, Tsai, Jih-Jin, additional, Wu, Yi-Chieh, additional, Lai, Chih-Yun, additional, Lu, Chih-Hsuan, additional, Huang, Jyh-Hsiung, additional, Chang, Gwong-Jen, additional, Wu, Han-Chung, additional, and Wang, Wei-Kung, additional

Published
2012
Full Text
View/download PDF

21. Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

Author

Lai, Chih-Yun, primary, Tsai, Wen-Yang, additional, Lin, Su-Ru, additional, Kao, Chuan-Liang, additional, Hu, Hsien-Ping, additional, King, Chwan-Chuen, additional, Wu, Han-Chung, additional, Chang, Gwong-Jen, additional, and Wang, Wei-Kung, additional

Published
2008
Full Text
View/download PDF

23. Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

Author

Patel, Bhumi, Williams, Katherine L., de Alwis, Ruklanthi, Lai, Chih-Yun, Harris, Eva, Crowe, James E., Smith, Scott A., de Silva, Aravinda M., Schmid, Michael A., and Wang, Wei-Kung

Subjects
viruses, virus diseases, biochemical phenomena, metabolism, and nutrition, 3. Good health
Abstract

Dengue viruses (DENV) are mosquito-borne flaviviruses of global importance. DENV exist as four serotypes, DENV1-DENV4. Following a primary infection, individuals produce DENV-specific antibodies that bind only to the serotype of infection and other antibodies that cross-react with two or more serotypes. People exposed to a secondary DENV infection with another serotype are at greater risk of developing more severe forms of dengue disease. The increased risk of severe dengue in people experiencing repeat DENV infections appear to be due, at least in part, to the ability of pre-existing serotype cross-reactive antibodies to form virus-antibody complexes that can productively infect Fcγ receptor-bearing target cells. While the theory of antibody-dependent enhancement (ADE) is supported by several human and small animal model studies, the specific viral antigens and epitopes recognized by enhancing human antibodies after natural infections have not been fully defined. We used antibody-depletion techniques to remove DENV-specific antibody sub-populations from primary DENV-immune human sera. The effects of removing specific antibody populations on ADE were tested both in vitro using K562 cells and in vivo using the AG129 mouse model. Removal of serotype cross-reactive antibodies ablated enhancement of heterotypic virus infection in vitro and antibody-enhanced mortality in vivo. Further depletion studies using recombinant viral antigens showed that although the removal of DENV E-specific antibodies using recombinant E (rE) protein resulted in a partial reduction in DENV enhancement, there was a significant residual enhancement remaining. Competition ADE studies using prM-specific Fab fragments in human immune sera showed that both rE-specific and prM-specific antibodies in primary DENV-immune sera significantly contribute to enhancement of heterotypic DENV infection in vitro. Identification of the targets of DENV-enhancing antibodies should contribute to the development of safe, non-enhancing vaccines against dengue.

24. Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinsky, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, and Mongkolsapaya, Juthathip

Subjects
PUBLISHED errata, IMMUNOGLOBULINS, VIREMIA, DENGUE viruses, PERIODICAL publishing, PUBLISHING
Published
2015
Full Text
View/download PDF

25. Characterization of human antibodies against envelope protein of dengue virus during natural infection

Author

Lai, Chih-Yun

Subjects
serotype
Abstract

Despite decades of research to develop vaccines against dengue virus (DENV), there is no licensed dengue vaccine available, partly due to the lack of understanding of immune correlates of protection during natural infection. While neutralizing antibodies (Abs) against the envelope (E) protein of DENV are known to be protective, the role of different categories of anti-E Abs in protection and their epitopes remain unknown. The long-term goal of this study is to facilitate the development of a safe and effective dengue vaccine. The objective of the study is to elucidate the categories and epitopes of human anti-E Abs that account for neutralization during natural DENV infection. We hypothesize that after primary DENV infection, type-specific (TS) anti-E Abs are responsible for neutralization against the infecting serotype; after a secondary DENV infection, group-reactive (GR) anti-E Abs, the major component of cross-reactive Abs, correlate with neutralization against the non-exposed serotypes. In the first aim, we defined the role of TS anti-E Abs after primary DENV infection. We demonstrated that TS, rather than cross-reactive, anti-E Abs were responsible for the neutralizing activity and recognized structurally complex epitopes present on the virus particles rather than solubilized E protein. Moreover, we found that domain III of the E protein, though not the predominant epitope, was recognized by TS neutralizing Abs. In the second aim, we investigated the role of GR anti-E Abs in the neutralizing activity against non-exposed serotypes after secondary DENV infection. We demonstrated that the GR monoclonal antibodies derived from individuals with secondary DENV infection had stronger binding avidity and neutralization potency than those from individuals with primary infection, and blocked DENV at post-attachment step. This suggested that dengue immune status of the host (primary versus secondary DENV infection) affects the quality of cross-reactive Abs. In addition, we found that in the sera of 29 patients with secondary DENV infection from a Nicaraguan cohort, the concentration of antifusion loop Abs, which represents GR anti-E Abs, did not correlate with neutralization titers against the current infecting DENV serotype but correlated with neutralization titers against the non-exposed serotypes.

Published
2014

26. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.

Author

Lai CY, To A, Wong TAS, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Donini O, and Lehrer AT

Abstract

The speed at which several COVID-19 vaccines went from conception to receiving FDA and EMA approval for emergency use is an achievement unrivaled in the history of vaccine development. Mass vaccination efforts using the highly effective vaccines are currently underway to generate sufficient herd immunity and reduce transmission of the SARS-CoV-2 virus. Despite the most advanced vaccine technology, global recipient coverage, especially in resource-poor areas remains a challenge as genetic drift in naïve population pockets threatens overall vaccine efficacy. In this study, we described the production of insect-cell expressed SARS-CoV-2 spike protein ectodomain and examined its immunogenicity in mice. We demonstrated that, when formulated with CoVaccine HT™adjuvant, an oil-in-water nanoemulsion compatible with lyophilization, our vaccine candidates elicit a broad-spectrum IgG response, high neutralizing antibody titers, and a robust, antigen-specific IFN-γ secreting response from immune splenocytes in outbred mice. Our findings lay the foundation for the development of a dry-thermostabilized vaccine that is deployable without refrigeration.

Published
2021
Full Text
View/download PDF

27. CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation.

Author

Haun BK, Lai CY, Williams CA, Wong TA, Lieberman MM, Pessaint L, Andersen-Elyard H, and Lehrer AT

Abstract

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results